

*Increased bioavailability of phenolic acids and enhanced vascular function following intake of feruloyl esterase-processed high fibre bread: a randomized, controlled, single blind, crossover human intervention trial*

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Turner, A. L., Michaelson, L. V., Shewry, P. R., Lovegrove, A. and Spencer, J. P. E. (2021) Increased bioavailability of phenolic acids and enhanced vascular function following intake of feruloyl esterase-processed high fibre bread: a randomized, controlled, single blind, crossover human intervention trial. *Clinical Nutrition*, 40 (3). pp. 788-795. ISSN 0261-5614 doi: <https://doi.org/10.1016/j.clnu.2020.07.026> Available at <https://centaur.reading.ac.uk/93683/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1016/j.clnu.2020.07.026>

Publisher: Elsevier

including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

**Increased bioavailability of phenolic acids and enhanced vascular function following intake of feruloyl esterase-processed high fibre bread: a randomized, controlled, single blind, crossover human intervention trial.**

Alice L. Turner<sup>a</sup>, Louise V. Michaelson<sup>b</sup>, Peter R. Shewry<sup>b</sup>, Alison Lovegrove<sup>b</sup> and Jeremy P. E. Spencer<sup>a\*</sup>.

<sup>a</sup>Department of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, University of Reading, Reading. UK (ALT, JPES).

<sup>b</sup>Department of Plant Sciences, Rothamsted Research, Harpenden, UK (LVM, PRS, AL).  
School of Agriculture, Policy and Development, University of Reading, Reading, Berks. UK (PRS).

**Corresponding author:** \*JPE Spencer. Department of Food and Nutritional Sciences, University of Reading, Reading. UK. Tel: +44 (0) 118 378 8724 [j.p.e.spencer@reading.ac.uk](mailto:j.p.e.spencer@reading.ac.uk)

**Short Running Head:** Free FA bread and vascular function

**Clinical Trial Registry: No:** NCT03946293; **Website:** [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## 2 ABSTRACT

3 **Background and Aims:** Clinical trial data have indicated an association between wholegrain  
4 consumption and a reduction in surrogate markers of cardiovascular disease. Phenolics present in  
5 wholegrain bound to arabinoxylan fibre may contribute these effects, particularly when released  
6 enzymatically from the fiber prior to ingestion. The aim of the present study was therefore to  
7 determine whether the intake of high fibre bread containing higher free ferulic acid (FA) levels  
8 (enzymatically released during processing) enhances human endothelium-dependent vascular  
9 function.

10 **Methods:** A randomized, single masked, controlled, crossover, human intervention study was  
11 conducted on 19 healthy men. Individuals consumed either a high fibre flatbread with enzymatically  
12 released free FA (14.22 mg), an equivalent standard high fibre bread (2.34 mg), or a white bread  
13 control (0.48 mg) and markers of vascular function and plasma phenolic acid concentrations were  
14 measured at baseline, 2, 5 and 7 hours post consumption.

15 **Results:** Significantly increased brachial arterial dilation was observed following consumption of  
16 the high free FA ('enzyme-treated') high fibre bread verses both a white flatbread (2h:  $p<0.05$ ; 5h:  
17  $p<0.01$ ) and a standard high fibre flatbread (5h:  $p<0.05$ ). Concurrently, significant increases in  
18 plasma FA levels were observed, at 2 h ( $p<0.01$ ) after consumption of the enzyme-treated flatbread,  
19 relative to control treatments. Blood pressure, heart rate, DVP-SI and DVP-RI were not  
20 significantly altered following intake of any of the breads ( $p>0.05$ ).

21 **Conclusion:** Dietary intake of bread, processed enzymatically to release FA from arabinoxylan  
22 fiber during production increases the bioavailability of FA, and induces acute endothelium-  
23 dependent vasodilation.

24 **Key Words:** bioavailability, ferulic acid, vascular function, high fibre bread, human intervention,  
25 feruloyl esterase.

26

**Abbreviations:** Cardio-Vascular Disease (CVD), Flow Mediated Dilatation (FMD), Laser Doppler Imaging (LDI), Digital Pulse Wave (DVP), Blood Pressure (BP), acetylcholine (Ach), 3,5-Dichloro-4-hydroxybenzoic acid (3,5DHBA)

**Funding:**

This work was supported financially by the Biotechnology and Biological Sciences Research Council (BBSRC), UK (BB/M002802/1) and the BBSRC Diet and Health Research Industry Club (BB/L02540X/1). Rothamsted Research receives grant-aided support from the BBSRC of the UK and the work reported here forms part of the Designing Future Wheat Institute Strategic Programme [BB/P016855/1]; Tailoring Plant Metabolism [BBS/E/C/000I0420].

## 28 INTRODUCTION

29 Clinical data suggest that the regular intake of foods/beverages rich in phenolic compounds, such as  
30 cocoa, green tea, and berries, improves human vascular function and maintains a healthy circulatory  
31 function [1-4]. However, such foods/beverages tend to be expensive, have limited availability and  
32 are not consumed by large proportions of the population. Thus, to increase the intake of phenolic  
33 compounds at the population level, in a sustainable, economically viable way, requires their  
34 delivery through foods derived from staple crops such as rice, maize and wheat. Wholegrain wheat  
35 is a rich source of phenolic acids, in particular ferulic acid (FA) [5,6], in addition to vitamins,  
36 minerals, phytosterols, unsaturated fatty acids and lignans [7,8], and is consumed as both white and  
37 wholemeal breads and other cereal products. There is robust scientific evidence that diets rich in  
38 wholegrain have a beneficial effect on cardiovascular health [9-12] and current dietary guidelines  
39 emphasize the importance of wholegrain in the diet [13].

40 A number of components of wheat have been suggested to contribute to the cardiovascular health  
41 benefits associated with wholegrain consumption, most notably the fiber component [6,11,14,15].  
42 However, phenolic compounds that are bound to arabinoxylan fibre, particularly the  
43 hydroxycinnamate FA, may also contribute, in part, to vascular health effects [16-18]. FA  
44 comprises up to 90 % of the phenolic acids present in wholegrain wheat and is concentrated in the  
45 outer and aleurone layers of the grain (the bran) where it is present in three forms: as soluble free  
46 acid, soluble conjugates, and insoluble bound forms [6,19]. The latter constitute the majority of FA,  
47 and is covalently linked to arabinoxylan polysaccharides via stable ester bonds. Bound FA may also  
48 act as structural cross-links in cell walls, by oxidative dimerization [20]. Although cleavage of the  
49 ester linkage to release free FA is possible in the colon via fecal microbial xylanases and esterases,  
50 it is estimated that only about 25% of bound FA is released during this phase of digestion [21-24].  
51 Consequently, its liberation and absorption in the gastrointestinal tract and potential to induce  
52 beneficial vascular changes in humans is limited, although slow release and absorption of phenolic  
53 acids in the gut may contribute to the long-term benefits of regular wholegrain consumption [25].

54 In the present study, we produced high fibre bread with high amounts of free FA, released  
55 enzymatically during dough development, in order to determine whether dietary-relevant amounts  
56 of free FA delivered in high fibre bread are capable of inducing acute beneficial effects upon  
57 endothelial function.

## 58 **SUBJECTS AND METHODS**

### 59 **Production and composition of breads**

60 *Triticum aestivum* cv Hereward was grown at Rothamsted Research (Harpenden, UK) and milled by  
61 Campden BRI (Chipping Campden, UK) using a Buhler MLU-202 mill (Uzwil, Switzerland) to  
62 give 10 fractions; Reduction 1 (R1), Reduction 2 (R2), Reduction 3 (R3), Break 1 (B1), Break 2  
63 (B2), Break 3 (B3), Bran Flour (BF), Offal Flour (OF), Bran Off-tails (BO) and Offal Off-tails  
64 (OOT). Selected fractions were combined to produce experimental unleavened breads: white flour  
65 was prepared by combining breaks 1, 2 and 3 and reductions 1, 2 and 3 with an extraction rate of  
66 72.0% of total flour. 'High fibre' flour was prepared by combining 9 fractions: breaks 1, 2 and 3,  
67 reductions 1, 2 and 3, bran flour, offal flour, and offal off tails with an extraction rate of 85% of  
68 total flour. The bran off-tails were not included in the 'high fibre' flour as their coarse texture  
69 reduced the palatability of the breads. The FA content of the milled wheat fractions is shown in  
70 **Supplemental data, Table S1**. Intervention breads (unleavened, flatbreads) were produced by  
71 combining flour, water, enzyme (Ultraflo L<sup>®</sup>) and salt (**Table 1**) for 5 min using a Buhler mixer.  
72 Ultraflo L<sup>®</sup>, a commercial  $\beta$ -glucanase, which also possesses xylanase and feruloyl esterase  
73 activities, was used to release FA bound to arabinoxylan. For the breads used in the intervention  
74 study this enzyme mixture was diluted in water at a ratio of 95:5 (water:Ultraflo L<sup>®</sup>, (v/v)). Dough  
75 was made using flour, water (containing the 5% enzyme solution) and salt in the following  
76 proportions 60.5% flour; 38.7% water; 0.7% salt. The dough was left to prove for 4 hours in a  
77 temperature-controlled environment (20°C), before being divided into 50 g portions and rolled to 13  
78 cm x 2mm disks. The unleavened flatbreads were baked for 7 minutes at 230°C and left to cool.

79 The control breads (white and high fibre) contained deactivated Ultraflo L® (95°C for 30 minutes,  
80 then cooled on ice).

81

82 The white intervention bread differed in appearance to the high fiber breads due to the flours used  
83 in each, although there were no observable differences between the standard and enzyme-treated  
84 high fibre breads. The optimum conditions for enzymatic release of FA from arabinoxylan during  
85 dough proving were established prior to the production of breads for intervention (Supplementary  
86 Figures 2A and 2B). All breads were made at the same time and stored at -20°C until use. No  
87 significant degradation of FA was observed within breads following 2 or 4 weeks of storage at -  
88 20°C ( $p>0.05$ ) (data not shown).

89

90 Phenolic acids present in the original milling fractions ( $n=3$ ) (Supplementary Table S1) and in the  
91 final intervention breads ( $n=3$ ) (Table 1) were quantified as described by [6]. Briefly, after addition  
92 of an internal standard free phenolic acids were extracted from finely ground material in 80% (v/v)  
93 ethanol. Bound phenolics were determined in samples after the removal of free and conjugated  
94 phenolic acids. Internal standard was added to the remaining residue and 2M NaOH added to  
95 release the esterified phenolic acids. Following centrifugation, the supernatant was acidified with  
96 12M HCl, mixed thoroughly, ethyl acetate added, mixed and centrifuged again. The upper phase  
97 was removed, and the ethyl acetate extraction repeated a further two times. The combined  
98 supernatants are evaporated to dryness in a Speedvac. The dry sample was then re-suspended in 2%  
99 (v/v) acetic acid, centrifuged and FA levels quantified using an Agilent 1100 HPLC equipped with a  
100 diode array detector (as described by [6], using authentic standards and an internal standard (3,5-  
101 Dichloro-4-hydroxybenzoic acid). All fractions were dried prior to re-suspension in 2% (v/v) acetic  
102 acid. 50  $\mu$ l of each extract was separated using a Discovery RP-Amide C16 column (250 x4.6mm,  
103 5 $\mu$ m) maintained at 30°C. The mobile phases consisted of a mixture of acetonitrile (solution A)  
104 and 2% (v/v) acetic acid in water (solution B) with a flow rate of 1.0 mL/min. The following



105 gradient system was used (min/% B): 0/100, 30/85, 50/50, 70/30, with 10 min post-run for column  
106 re-equilibration. The wavelength used for quantification of FA was 280 nm and spectral  
107 characteristics were scanned over the range 200–600 nm. All data were analyzed using  
108 ChemStation software.

### 109 **Ethics**

110 The clinical trial was registered at clinicaltrials.gov (NCT03946293) and conducted according to  
111 the Declaration of Helsinki following Good Clinical Practice (GCP) and was approved for conduct  
112 by the University of Reading's Research Ethics Committee (ethics reference number 12/06). All  
113 volunteers signed an informed consent form before commencing the study.

### 114 **Intervention study population**

115 Healthy male volunteers ( $n = 19$ ) (**Figure 1**) were recruited from the University of Reading and  
116 surrounding areas by use of the Hugh Sinclair Unit volunteer database, poster advertisement within  
117 the university and local community via local websites. Volunteers were screened and selected  
118 according to the following inclusion criteria: 1) fasting lipids in the upper half of the normal range  
119 (triacylglycerol 0.8-3.2 mmol/l and total cholesterol 6.0-8.0 mmol/l); 2) BMI 25-32 kg/m<sup>2</sup>; 3) non-  
120 smoker; 4) not diabetic (diagnosed or fasting glucose < 7 mmol/l) or suffer from endocrine  
121 disorders; 5) hemoglobin and liver enzymes levels within the normal range [Alanine Transaminase  
122 (ALT): 0-55 IU/L; Alkaline Phosphatase (ALP): 38-126 U/L; Aspartate Transaminase (AST): 0-45  
123 IU/L; Gamma Glutamyl Transferase (GGT): 12-58 IU/L]); 6) not having suffered a myocardial  
124 infarction/stroke in the past 12 months; 7) not suffering from renal or bowel disease or have a  
125 history of cholestatic liver or pancreatitis; 8) not on drug treatment for hyperlipidemia,  
126 hypertension, inflammation or hyper-coagulation; 9) not taking any fish oil, fatty acid or vitamin  
127 and mineral supplements; 10) no history of alcohol misuse; 11) not planning, or on a weight  
128 reduction regime; 12) not having taken antibiotics in the 6 months prior to the study; and 13) being  
129 able to consume the study interventions. The 19 individuals selected for the study were instructed

130 not to alter their usual dietary or fluid intake, with respect to amount consumed. Volunteers were  
131 requested to refrain from the following, 24 h prior to, and during, the study visits: 1) consumption  
132 of polyphenol-rich foods including fruits, vegetables, wholegrain bread/pasta/rice, cocoa, coffee, tea  
133 and wine; 2) participating in vigorous exercise (> 3 x 20 min/week); and 3) consuming more than  
134 168 g of alcohol (any form) per week. Volunteers were further asked to fast for 12 hours before  
135 each study visit and during that period only consume low-nitrate water provided. The Baseline  
136 characteristics of the study population are presented in Table 1.

### 137 **Study design**

138 The study was a randomized, single blind, crossover, controlled intervention trial in which subjects  
139 attended the Hugh Sinclair Unit of Human Nutrition on 3 separate occasions. We considered the  
140 trial to be single blinded (researcher) as interventions differed slightly in appearance, although no  
141 information regarding the interventions could be implied from this. Visits were separated by at  
142 least 2 weeks, and treatments to subjects were allocated randomly using a restricted Williams  
143 design (as patients were recruited sequentially) by an independent researcher, who implemented the  
144 allocation sequence on the first visit. On arrival, subjects were rested in the supine position for at  
145 least 30 minutes in a quiet, air-conditioned environment (22-24°C), during which time they were  
146 cannulated for venous blood collection and baseline vascular measurements were taken, including  
147 FMD of the brachial artery (primary outcome), laser Doppler imaging (LDI) with iontophoresis,  
148 and digital pulse wave (DVP), and systolic and diastolic blood pressure (Omron MX2 automatic  
149 digital upper arm blood pressure monitor). Following collection of baseline measurements,  
150 volunteers were requested to consume three 30 g flatbreads (white, standard high fibre, or enzyme-  
151 treated high fibre) within a 5 min period and further blood was collected at 1, 2, 3, 4, 5, 6 and 7 h  
152 and vascular measurements were conducted at 2, 5 and 7 h. Volunteers were provided with a low-  
153 fat, low-polyphenol lunch (consisting of 2 slices of white bread, low fat cream cheese containing  
154 3% fat, lightly salted crisps and a low-fat vanilla yoghurt) at 3 h and had free access to bottled water  
155 containing low nitrate/nitrite levels) throughout the study day. Following completion of each

156 experimental arm, participants followed a washout period of 14 days prior, where they were asked  
157 to follow their normal habitual diet, before switching to an alternate arm of the trial. A qualified  
158 nurse was responsible for cannulation and blood collection. All study personnel, including research  
159 nurses and research staff were blinded to the interventions. The study followed ethical standards,  
160 which were in accordance with the University of Reading Ethics Committee. No changes were  
161 made to any of the trial methods or outcomes following the commencement of the trial.  
162 Recruitment for the trial took place between Oct 2012 and February 2013, whilst the trial was  
163 conducted between January 2013 and January 2014.

#### 164 **Flow Mediated Dilatation (FMD)**

165 Subjects were positioned into the supine position with the right arm rested on a custom-made arm  
166 support at a 90° angle with their hand facing towards the ceiling. Electrocardiogram (ECG) pads  
167 were attached to time each image frame with respect to the cardiac cycle. A sphygmomanometric  
168 cuff was placed on the forearm and an image of the longitudinal brachial artery was obtained using  
169 a 3.5 x 1.0 cm hockey-stick probe, attached to a flexible holding device with locking action to allow  
170 for accurate measurements, and ATL Ultrasound HDI5000 broadband ultrasound system. The live  
171 image was captured using image-grabbing software (MIA-11c) and collected images at 0.25  
172 frames/second. A baseline measurement was recorded for 40 seconds using the flow. After this the  
173 main FMD measurement was started by recording the image for 60 seconds before arterial  
174 occlusion was created by inflating the cuff to 220mmHg causing ischemia of the arterial vessel.  
175 After 5 minutes the cuff was deflated, rapidly causing a decrease in pressure leading to reactive  
176 hyperemia to accommodate the dilated resistance levels. Image collection continued for 5 minutes  
177 post release and analysis of the arterial diameter was performed to assess the flexibility of the artery  
178 calculated as the relative diastolic diameter change from baseline compared to the peak diastolic  
179 diameter. Analysis was performed using a semi-automated computerized analysis system (Brachial  
180 Analyzer; Medical Imaging Applications-11c). In order to avoid potential inter-individual, and  
181 intra-individual variability of measurements within our experimental group, the same researcher

182 conducted all FMD measurements. Additionally, care was taken to conduct brachial artery flow-  
183 mediated dilatation measurements consistently, with probe placements and cuff positioning  
184 carefully recorded and replicated between and across individuals.

185

### 186 **Laser Doppler Imaging with iontophoresis (LDI)**

187 The assessment of peripheral microvascular function [26,27] was conducted via the administration  
188 of an endothelial-dependent vasodilator, acetylcholine ACh (1%), and an endothelium in-dependent  
189 vasodilator, sodium nitroprusside (SNP) (1%), to the skin, which were delivered transdermally  
190 using iontophoresis. Subjects were rested in the supine position, with their right arm supported by  
191 an armrest. Two ION 6 chambers were applied to the forearm, within 1cm of each other, using  
192 double sided adhesive disks. 2.5ml of freshly prepared ACh (1% w/v in 0.5% (w/v) NaCl solution;  
193 Sigma Aldrich, Poole, Dorset, UK) was introduced to the anodal chamber and 2.5ml of SNP (1%  
194 w/v in 0.5% (w/v) NaCl solution; Sigma Aldrich, Poole, Dorset, UK) into the cathodal chamber. A  
195 coverslip was placed over each chamber to prevent any liquid from escaping. After baseline of skin  
196 perfusion was measured, an incremental electrical current was delivered simultaneously across the  
197 two chambers using the laser Doppler imager (LD12-VR) and MIC2 iontophoresis controller (Moor  
198 instruments Ltd) (increased in 5 $\mu$ A steps; 5, 10, 15 and 20  $\mu$ A to yield a total charge of 8  
199 milliCoulombs within 12 minutes). A total of 20 scans were performed. An indicator of  
200 microvascular response due to ACh and SNP was calculated by the area under the flux versus time  
201 curve during the 20 scans.

### 202 **Digital Volume Pulse (DVP)**

203 The DVP stiffness index (DVP-SI) and DVP reflexion index (DVP-RI) was calculated by placing a  
204 PulseTrace PCA 2 with a photoplethysmograph transducer (MircoMedical, Kent) on the index  
205 finger of the left hand, transmitting an infrared light at 940nm. DVP was conducted as previously  
206 described [28-30]. The infrared light transmission through the finger records the systolic and  
207 diastolic waveforms of the pulse, and also records the stiffness index (DVP-SI) and reflexion index

208 (DVP-RI). The DVP-SI (in m/s) is related to large arterial stiffness and is measured by dividing the  
209 height of the subject by the time between the first and the second wave peaks of the DVP. It is  
210 related to CVD risk factors such as blood pressure, age and waist to hip ratio. The DVP-RI is  
211 related to smaller artery stiffness and is defined as the relative height of the second peak compared  
212 with the first.

### 213 **Plasma FA analysis**

214 Blood was collected at baseline and 1, 2, 3, 4, 5,6 and 7h after ingestion and processed as described  
215 in [31] and analyzed as follows. LC-MS analysis, as described by [32], with minor modifications  
216 was also used to assess FA levels and other phenolic acids in human plasma samples. Measurements  
217 were performed on an ABSciex 4000QTRAP MS system linked to an Agilent 1200 HPLC, column  
218 oven set to 30 °C, flow rate 200 µl/min. The column eluent was introduced into the mass spectrometer  
219 by a TurboIonSpray probe operating at 475 °C, with ion spray voltage set in negative mode to -4500  
220 V. Both the nebulizer gas pressure (GS1) and turbo heater gas (GS2) were set to 60 psi. The curtain  
221 gas flow was set to 25 l/min. The MS data were collected in MRM scan mode with compound-  
222 dependent parameters.

### 223 **Data handling, power calculations and statistical analysis**

224 The power calculation was based on the primary clinical outcome measure (FMD of the brachial  
225 artery) in order to determine the minimum number of participants required for the study. The  
226 minimal physiologically significant improvement on FMD measurable is an absolute change of  
227 between 1 to 2 % in FMD, considering a baseline vasodilatation of 4-6 %. The sample size was  
228 calculated based on the variance of repeated measurement in the control group and on control data.  
229 Consequently, with a standard deviation within patients of 2.3% (based on previous studies  
230 performed in our group), a significance level of 0.05 and a power of 80%, 18 subjects were required  
231 in order to determine a significant within-subject difference between treatments of at least 2.1%.  
232 Two-way repeated measured ANOVA was used to analyze all data using GraphPad Prism version 4  
233 (GraphPad Software Inc., San Diego, CA, US). Post hoc analysis was conducted using a Bonferroni

234 multiple comparisons test. Significance was defined as  $P < 0.05$ , with  $P$  values represented in the  
235 figures as \*  $P = 0.01-0.05$ , \*\*  $P = 0.001-0.01$ , \*\*\*  $P = < 0.001$ , \*\*\*\*  $P = < 0.0001$ . The incremental  
236 area under the LDI flux versus time curve (IAUC) was calculated using the trapezoidal method.  
237 Prism (GraphPad software, USA) was used to analyze the data. Differences by treatment were  
238 identified using a two-way ANOVA with repeated measures. Post hoc analysis was subjected to  
239 Bonferroni correction.  $P$  values less than 0.05 were treated as significant.

240

## 241 **RESULTS**

### 242 **Baseline measurements**

243 All baseline measurements of the subjects were within the normal range (**Table 2**) including blood  
244 pressure and FMD. All treatments were well tolerated, with only one participant withdrawing due to  
245 an adverse event (gastrointestinal discomfort on both high fibre interventions).

246

### 247 **Release of free FA from flatbreads**

248 The levels of free, conjugated and bound FA in the white and high fibre flatbreads are presented in  
249 Table 1. Enzyme treatment of high fibre bread resulted in the release of more than 60 % of bound  
250 FA, with 30g of enzyme-treated high fibre flatbread providing 4.74 mg of *free* FA, compared to  
251 0.78 mg in standard high fibre and 0.16 mg in white bread. Three flatbreads were provided per  
252 treatment, delivering a 22.21mg of *total* FA after consumption of the enzyme-treated high fibre  
253 flatbread, compared to 18.87mg from the non-enzyme treated high fibre flatbread and 1.38mg from  
254 the white flatbread control.

255

**256 Vascular function**

257 A time-dependent increase in FMD was observed following consumption of the enzyme-treated  
258 high fibre bread with significantly increased brachial arterial dilation at 2 h ( $p<0.05$ ), 5 h ( $p<0.01$ )  
259 and 7 h ( $p<0.05$ ), relative to the white bread and at 5 h ( $p<0.01$ ), relative to non-treated high fibre  
260 control (n = 19) (**Figure 2**). FMD increased by  $0.9 \pm 0.5\%$  at 2 h,  $1.5 \pm 1.1\%$  at 5 h and  $1.2 \pm 0.9\%$   
261 at 7 h for the enzyme-treated high fibre flatbread, relative to baseline. No significant differences in  
262 FMD were observed at baseline between groups ( $p>0.05$ ) or following intake of either the white  
263 bread or the non-treated high fibre bread, relative to baseline ( $p>0.05$ ), although FMD levels were  
264 elevated following consumption of non-treated high fibre flatbread at 7 h ( $p = 0.098$ , n = 19).  
265 Blood pressure, heart rate, DVP-SI and DVP-RI were not significantly altered following the  
266 consumption of any of the breads (Table 2) or between baseline and post intervention ( $p>0.05$ ; 2-  
267 way ANOVA with Bonferroni post-hoc analysis). Following consumption of the enzyme-treated  
268 high fibre bread, there was a rise in endothelium-dependent vasodilation (as indicated by increases  
269 in skin erythrocyte flux in the presence of acetylcholine chloride) at 5h and a return to baseline at 7h  
270 (**Figure 3 (A)**), although this was not statistically significant. Similarly, no changes were  
271 observed in response to SNP (endothelium independent) for any of the treatments (**Figure 3 (B)**).

272

**273 Plasma ferulic acid analysis**

274 No significant increases in total plasma phenolic acids were observed over the 7 h period (**Figure**  
275 **4(A)**). However, a significant increase in plasma ferulic acid was observed following intake of the  
276 enzyme-treated high fibre flatbread at 2 h ( $p<0.001$ ) and 5 h ( $p<0.01$ ), versus white bread and at 2 h  
277 ( $p<0.001$ ) and 5 h ( $p<0.05$ ), versus non-treated high fibre control (**Figure 4 (B)**). None of the other  
278 individual phenolic acids measured in the study differed between treatments ( $p < 0.05$ ;

**279 Supplementary Figure S2).**

280

281 **DISCUSSION**

282 In the present study, we show improved acute vascular function following the consumption of the  
283 high fibre flatbread which had been treated with an esterase enzyme to release FA bound to  
284 arabinoxylan fibre. The release of FA during bread making resulted in a significantly higher level  
285 of ferulic acid reaching the circulation (relative to control breads) and resulted in a significant  
286 increase in FMD at 2 ( $p<0.05$ ) and 5 h ( $p<0.01$ ) compared to both the high fibre and white flatbread  
287 controls (Figure 2). These results are in agreement with a study which showed that intake of wine  
288 containing a similar amount of phenolic acids improves endothelial-independent vasodilation  
289 acutely in healthy volunteers [33]. Furthermore, with respect to FMD effect size, our data are also  
290 in agreement with previous data sets showing increases in brachial artery dilation at 1-2 and 6 h  
291 following ingestion of, for example the equivalent of 240g fresh weight of blueberries (containing  
292 766-1791 mg of polyphenols) [34], cocoa [35, 36], red wine [37] and decaffeinated coffee [38].

293

294 The increase in FMD observed in response to the enzyme-treated high fibre flatbread was paralleled  
295 by an increase in plasma FA. Previous studies have reported free FA concentrations in plasma of  
296 between 150-210 nM at 1 to 3 hours post consumption of a high bran cereal [39] and  
297 640 $\mu$ mol/min/L after consumption of bread [40], with these foods delivering phenolics primarily in  
298 the bound-form with no attempt to release FA prior to consumption. There is evidence that FA can  
299 be released from arabinoxylan via the action of microbiota-derived esterases and xylanases [21,41-  
300 43], although this appears to be of limited efficiency, with only about 25% released by fecal  
301 esterases [21,44,45]. Previous work has also shown that processing (fermentation and enzyme  
302 treatment) of wheat bran can increase free FA in bread by up to 8-fold [46] and lead to increased  
303 release of FA in the colon, and consequently increases in derived metabolites such as 3,4-  
304 dihydroxyphenylpropionic acid, 3-hydroxyphenylpropionic acid and 3-phenylpropionic acid. Such  
305 bioprocessed bread has been shown to increase the bioavailability of phenolic acids and lead to  
306 subsequent immunomodulatory effects in humans [40].



307

308 With respect to mechanism of action, there are very few studies regarding the physiological actions  
309 of FA and its metabolites on endothelial function. Animal studies indicate the potential for FA to  
310 improve endothelium dysfunction in aortas of rats with spontaneous hypersensitivity [47], and in  
311 conjunction with astragaloside IV in streptozotocin-induced diabetic rats [48]. Both studies  
312 concluded that FA increased NO bioavailability via a decrease in NADPH-dependent superoxide  
313 anion levels [47] and by regulating eNOS activity [48]. In humans, the intake of oats, which is also  
314 rich in FA and other phenolics, has been shown to enhance the FMD response in overweight,  
315 dyslipidemic adults, particularly in post-menopausal women [49], providing further support for an  
316 NO-mediated mechanism. In addition to such a pathway of activity, it has also been suggested that  
317 the intake of any cereal food rich in aleurone cells (which have high contents of fibre, phenolics and  
318 other potentially beneficial components) may also improve markers of immune function status, such  
319 as C-reactive protein and adhesion molecules [50]. Additional support for the causal activity of  
320 phenolic acids in vascular benefits, comes from the late improvement in FMD following  
321 consumption of the untreated high fibre bread, in the current study, where the excretion of total  
322 phenolic acids was highest. Such metabolites include isoferulic acid, hippuric acid and  
323 protocatechuic acid, metabolites known to be products of hydroxycinnamic acids, after bacterial  
324 metabolism in the large intestine [51-53]. Similarly, small phenolic metabolites derived from  
325 anthocyanin and chlorogenic acid were proposed to mediate improvements in FMD at 6 h post-  
326 consumption of blueberry flavonoids [33].

327

328 Another potential mechanism may involve an increase in steady-state NO levels, via inhibition of  
329 NADPH oxidase. Ferulic acid may inhibit NADPH oxidase, in a similar manner to the structurally  
330 related drug apocynin, thus reducing superoxide levels. This reduction in superoxide formation  
331 may maintain nitric oxide levels by limiting the reaction of nitric oxide with superoxide (to form  
332 peroxynitrite) and consequently sparing nitric oxide bioavailability to the vasculature. Inhibition of

333 NADPH oxidase activity by phenolic metabolites, such as FA and isoferulic acid, has been  
334 observed in clinical trials following intake of blueberry polyphenols, which occurred concurrently  
335 with an increase in FMD [33] and has been noted in cell studies with flavanols [54,55]. FA, and its  
336 metabolites, have structural homology to apocynin, a known NADPH oxidase inhibitor [56], with  
337 ferulic, vanillic, homovanillic, and hippuric acids, as well as tyrosol and hydroxytyrosol, all  
338 possessing significant inhibitory activity [55, 56] . Further investigation is required to define the  
339 detailed mechanism by which wholegrain phenolics exert their activity in humans, however, it  
340 appears likely that the interactions of these small phenolics with the endothelium and its local  
341 environment may underpin such physiological events.

342 In conclusion, this study has shown that enzymatic processing of high fibre bread can increase the  
343 bioavailability of FA and lead to improvements in human vascular function. Our data also suggest  
344 that the global influence of wholegrain intake on human cardiovascular health may also relate to the  
345 combined influence of both fibre and phenolic acids present within the wholegrain. Further  
346 development of innovative baking and bread processing techniques, such as enzymatic treatment of  
347 dough to release potential bioactives, may represent a promising approach to improve the bio-  
348 accessibility of these beneficial components of wholegrain in a cost-effective way to a wide section  
349 of the population.

350

#### 351 **ACKNOWLEDGEMENTS**

352 Rothamsted Research receives grant-aided support from the Biotechnology and Biological Sciences  
353 Research Council (BBSRC) of the UK and the work reported here forms part of the Designing  
354 Future Wheat Institute Strategic Programme (AL and PRS) [BB/P016855/1] and LVM Tailoring  
355 Plant Metabolism [BBS/E/C/000I0420].

#### 356 **Conflict of Interest (COI) Statement**

357 The authors have declared no conflict of interest.

358

359 **Authors' Contributions**

360 Study design (PRS, JPES), phenolic analysis (AA), human study implementation (AA), solid phase  
361 extraction (AA), mass spectrometry (LVM, AL), statistical analysis (AA, JPES), data interpretation  
362 (AA, AL, PRS, JPES), manuscript preparation (AA, AL, PRS, JPES), manuscript approval (AA,  
363 LVM, AL, PRS, JPES).

## REFERENCES

- [1] Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ, Spencer JP. Polyphenols and human health: prevention of disease and mechanisms of action. *Nutrients* 2010; 2: 1106-31.
- [2] Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. *American Journal of Medicine* 2015; 128: 229–38.
- [3] Tresserra-Rimbau A, Rimm EB, Medina-Remon A, Martinez-Gonzalez MA, de la Torre R, Corella D, et al. Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. *Nutrition Metabolism and Cardiovascular Diseases*. 2014; 24: 639–47.
- [4] Khan, N.; Khymenets, O.; Urpí-Sardà, M.; Tulipani, S.; Garcia-Aloy, M.; Monagas, M.; Mora-Cubillos, X.; Llorach, R.; Andres-Lacueva, C. Cocoa Polyphenols and Inflammatory Markers of Cardiovascular Disease. *Nutrients* 2014; 6: 844-880.
- [5] Wang, L., Yao, Y., He, Z., Wang, D., Liu, A., Zhang, Y. Determination of phenolic acid concentrations in wheat flours produced at different extraction rates. *Journal of Cereal Science* 2013; 57: 67–72.
- [6] Li L, Shewry PR, Ward JL. Phenolic Acids in Wheat Varieties in the HEALTHGRAIN Diversity Screen. *Journal of Agricultural and Food Chemistry* 2008; 56: 9732-9739.
- [7] Borneo R, Leon AE. Whole grain cereals: functional components and health benefits. *Food and Function* 2012; 3: 110-9.
- [8] Belobrajdic DP, Bird AR. The potential role of phytochemicals in wholegrain cereals for the prevention of type-2 diabetes. *Nutrition Journal* 2013; 12: 62.
- [9] Jonnalagadda SS, Harnack L, Liu RH, McKeown N, Seal C, Liu S, Fahey GC. Putting the whole grain puzzle together: health benefits associated with whole grains--summary of American Society for Nutrition 2010 Satellite Symposium. *Journal of Nutrition* 2011; 141: 1011S-22S.
- [10] Mellen, PB, Walsh, TF & Herrington, DM. Whole grain intake and cardiovascular disease: a meta-analysis. *Nutrition Metabolism and Cardiovascular Disease* 2008; 18: 283–290.
- [11] Aune, D., Keum, N., Giovannucci, E., Fadnes, L.T., Paolo Boffetta, P., Greenwood, D.C., Tonstad, S., Vatten, L.J., Riboli, E., Norat, T. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. *British Medical Journal* 2016; 353: i2716.
- [12] Qing Ye, E, Chacko, SA, Chou, E.L., Kugizaki, M., Liu, S. Greater whole-grain intake is associated with lower risk of Type 2 diabetes, cardiovascular disease, and weight gain. *Journal of Nutrition*. 2012; 142: 1304–1313.
- [13] Scientific Advisory Committee on Nutrition (2014) Draft SACN Carbohydrates and Health Report. <https://www.gov.uk/government/consultations/consultation-on-draft-sacn-carbohydrates-and-health-report>.
- [14] Wei, H., Gao, Z., Liang, R., Li, Z., Hao, H., Liu, X. Whole-grain consumption and the risk of all-cause, CVD and cancer mortality: a meta-analysis of prospective cohort studies *British Journal of Nutrition*. 2016; 116: 514-525.
- [15] Qi L, Meigs JB, Liu S, Manson JE, Mantzoros C, Hu FB. Dietary fibers and glycemic load, obesity, and plasma adiponectin levels in women with type 2 diabetes. *Diabetes Care* 2006; 29: 1501-5.
- [16] Buscemi S, Verga S, Batsis JA, Tranchina MR, Belmonte S, Mattina A, Re A, Rizzo R, Cerasola G. Dose-dependent effects of decaffeinated coffee on endothelial function in healthy subjects. *European Journal of Clinical Nutrition* 2009; 63: 1200-1205.

- [17] Bach Knudsen K.E., Nørskov, N.P., Bolvig, A.K., Hedemann, M.S., Nygaard Lærke, H. Dietary fibre and associated phytochemicals in cereals. *Molecular and Nutritional Food Research* 2017; 61: 7.
- [18] Reboredo-Rodríguez, P., Varela-López, A., Forbes-Hernández, T.Y., Gasparri, M., Sadia Afrin, S., Cianciosi, D., Zhang, J., Pira Pia Manna, P., Bompadre, S., Quiles, J.L., Battino, M., Giampieri, F. Phenolic Compounds Isolated from Olive Oil as Nutraceutical Tools for the Prevention and Management of Cancer and Cardiovascular Diseases. *International Journal of Molecular Sciences*. 2018; 19: 2305.
- [19] Adom KK, Liu RH. Antioxidant Activity of Grains. *Journal of Agricultural and Food Chemistry* 2002; 50: 6182-6187.
- [20] Stone B, Morell M K Carbohydrates, in Khan K and Shewry P R, *Wheat: Chemistry and Technology*, 4<sup>th</sup> ed, 2009 St Paul, MN, AACC, 299-362.
- [21] Andreasen MF, Kroon PA, Williamson G, Garcia-Conesa M-T. Esterase activity able to hydrolyze dietary antioxidant hydroxycinnamates is distributed along the intestine of mammals. *Journal of Agricultural and Food Chemistry* 2001a; 49: 5679-5684.
- [22] Crozier, A.; Jaganath, I. B.; Clifford, M. N. Dietary phenolics: Chemistry, bioavailability and effects on health. *Natural Products Report*. 2009; 26: 1001–1043.
- [23] Faulds, C.B. What can feruloyl esterases do for us? *Phytochemical Review* 2010; 9: 121-132.
- [24] Vollmer, M., Esders, S., Farquharson, F.M., Neugart, S., Duncan, S.H., Schreiner, M., Louis, P., Maul, R., Rohn, S. Mutual Interaction of Phenolic Compounds and Microbiota: Metabolism of Complex Phenolic Apigenin-C- and Kaempferol-O-Derivatives by Human Fecal Samples. *Journal of Agricultural and Food Chemistry* 2018; 66:485-497.
- [25] Vitaglione P, Napolitano A, Fogliano V. Cereal dietary fibre: a natural functional ingredient to deliver phenolic compounds into the gut. *Trends in Food Science & Technology* 2008; 19: 451-463.
- [26] Morris SJ, Shore AC. Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms. *The Journal of Physiology* 1996; 496: 531-542.
- [27] Ferrell WR, Ramsay JE, Brooks N, Lockhart JC, Dickson S, McNeece GM, Greer IA, Sattar N. Elimination of Electrically Induced Iontophoretic Artefacts: Implications for Non-Invasive Assessment of Peripheral Microvascular Function. *Journal of Vascular Research* 2002; 39: 447-455.
- [28] Ramsay JE, Ferrell WR, Greer IA, Sattar N. Factors critical to iontophoretic assessment of vascular reactivity: implications for clinical studies of endothelial dysfunction. *Journal of Cardiovascular Pharmacology* 2002; 39: 9-17.
- [29] Wykretowicz A, Gerstenberger P, Guzik P, Milewska A, Krauze T, Adamska K, Rutkowska A, Wysocki H. Arterial stiffness in relation to subclinical atherosclerosis. *European Journal of Clinical Investigation* 2009; 39: 11-16.
- [30] Millasseau SC, Kelly RP, Ritter JM, Chowienczyk PJ. The vascular impact of aging and vasoactive drugs: comparison of two digital volume pulse measurements. *American Journal of Hypertension* 2003; 16: 467-472.
- [31] de Ferrars, R. M., Czank, C., Saha, S., Needs, P. W., Zhang, Q., Raheem, K. S., Kroon, P. A., Kay, C. D., Methods for isolating, identifying and quantifying anthocyanin metabolites in clinical samples. *Analytical Chemistry* 2014; 86: 10052-10058.
- [32] Nørskov, N.P., Hedemann, M.S., Theil, P. K., Fomsgaard, I.S., Laursen, B.B., & Bach Knudsen, K.E. Phenolic Acids from Wheat Show Different Absorption Profiles in Plasma: A Model Experiment with Catheterized Pigs. *Journal of Agriculture and Food Chemistry*. 2013; 61: 8842–8850.
- [33] Vauzour DEJH, George TW, Corona G, Garnotel R, Jackson KG, Sellier C, Gillery P, Kennedy OB, Lovegrove JA, Spencer JPE. Moderate Champagne consumption promotes an

- acute improvement in acute endothelial-independent vascular function in healthy human volunteers. *British Journal of Nutrition* 2010; 103: 1168-1178.
- [34] Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW, Heiss C, Spencer JP. Intake and time dependence of blueberry flavonoid-induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. *The American Journal of Clinical Nutrition* 2013; 98: 1179-1191.
- [35] Heiss C, Kleinbongard P, Dejam A, Perré S, Schroeter H, Sies H, Kelm M. Acute Consumption of Flavanol-Rich Cocoa and the Reversal of Endothelial Dysfunction in Smokers. *Journal of the American College of Cardiology* 2005; 46: 1276-1283.
- [36] Shrimel MG, Bauer SR, McDonald AC, Chowdhury NH, Coltart CE, Ding EL. Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. *The Journal of Nutrition* 2011; 141: 1982-1988.
- [37] van Bussel BCT, Henry RMA, Schalkwijk CG, Dekker JM, Nijpels G, Feskens EJM, Stehouwer CDA. Alcohol and red wine consumption, but not fruit, vegetables, fish or dairy products, are associated with less endothelial dysfunction and less low-grade inflammation: the Hoorn Study. *European Journal of Nutrition*. 2018; 57: 1409-1419.
- [38] Buscemi, S., Verga, S., Batsis, J. A., Tranchina, M. R., Belmonte, S., Mattina, A., Re, A., Rizzo, R. & Cerasola, G.. Dose-dependent effects of decaffeinated coffee on endothelial function in healthy subjects. *European Journal of Clinical Nutrition*. 2009;63:1200-1205.
- [39] Kern SM, Bennett RN, Mellon FA, Kroon PA, Garcia-Conesa M-T. Absorption of Hydroxycinnamates in Humans after High-Bran Cereal Consumption. *Journal of Agricultural and Food Chemistry* 2003; 51: 6050-6055.
- [40] Mateo Anson N, Aura AM, Selinheimo E, Mattila I, Poutanen K, Van Den Berg R, Havenaar R, Bast A, Haenen GRMM. Bioprocessing of wheat bran in whole wheat bread increases the bioavailability of phenolic acids in men and exerts anti-inflammatory effects *ex vivo*. *The Journal of Nutrition* 2011; 141: 137-143.
- [41] Kroon PA, Faulds CB, Ryden P, Robertson JA, Williamson G. Release of Covalently Bound FA from Fiber in the Human Colon. *Journal of Agricultural and Food Chemistry* 1997; 45: 661-667.
- [42] Andreasen MF, Kroon PA, Williamson G, Garcia-Conesa M-T. Intestinal release and uptake of phenolic antioxidant diFAs. *Free Radical Biology and Medicine* 2001b; 31: 304-314.
- [43] Buchanan CJ, Wallace G, Fry SC, Eastwood MA. In vivo release of <sup>14</sup>C-labelled phenolic groups from intact dietary spinach cell walls during passage through the rat intestine. *Journal of the Science of Food and Agriculture* 1996; 71: 459-469.
- [44] Stalmach, A., Steiling, H., Williamson, G., Crozier, A. 2010. Bioavailability of chlorogenic acids following acute ingestion of coffee by humans with an ileostomy. *Arch. Biochem. Biophys.* 501; 1: 98–105.
- [45] Williamson, G., Clifford, M.N. 2017. Role of the small intestine, colon and microbiota in determining the metabolic fate of polyphenols. *Biochemical Pharmacology* 139:24–39.
- [46] Anson NM, Selinheimo E, Havenaar R, Aura A-M, Mattila I, Lehtinen P, Bast A, Poutanen K, Haenen GRMM. Bioprocessing of wheat bran Improves in vitro bioaccessibility and colonic metabolism of phenolic compounds. *Journal of Agricultural and Food Chemistry* 2009; 57: 6148-6155.
- [47] Suzuki A, Yamamoto M, Jokura H, Fujii A, Tokimitsu I, Hase T, Saito I. FA restores endothelium-dependent vasodilation in aortas of spontaneously hypertensive rats. *American Journal of Hypertension* 2007; 20: 508-513.
- [48] Yin Y, Qi F, Song Z, Zhang B, Teng J. FA combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats. *Bioscience Trends* 2014; 8: 217-226.
- [49] Katz DL, Evans MA, Chan W, Nawaz H, Comerford BP, Hoxley ML, Njike VY, Sarrel PM. Oats, antioxidants and endothelial function in overweight, dyslipidemic adults. *Journal of the American College of Nutrition* 2004; 23: 397-403.

- [50] Price RK, Wallace JM, Hamill LL, Keaveney EM, Strain J, Parker MJ, Welch RW. Evaluation of the effect of wheat aleurone-rich foods on markers of antioxidant status, inflammation and endothelial function in apparently healthy men and women. *British Journal of Nutrition* 2012; 108: 1644-1651.
- [51] Rechner AR, Spencer JP, Kuhnle G, Hahn U, Rice-Evans CA. Novel biomarkers of the metabolism of caffeic acid derivatives in vivo. *Free Radical Biology and Medicine* 2001; 30: 1213-1222.
- [52] Caccetta RA-A, Croft KD, Beilin LJ, Puddey IB. Ingestion of red wine significantly increases plasma phenolic acid concentrations but does not acutely affect ex vivo lipoprotein oxidizability. *The American Journal of Clinical Nutrition* 2000; 71: 67-74.
- [53] Choudhury R, Srai SK, Debnam E, Rice-Evans CA. Urinary excretion of hydroxycinnamates and flavonoids after oral and intravenous administration. *Free Radical Biology and Medicine* 1999; 27: 278-286.
- [54] Steffen Y, Gruber C, Schewe T, Sies H. Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. *Archives of Biochemistry and Biophysics* 2008; 469: 209-219.
- [55] Steffen Y, Schewe T, Sies H. (-)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase. *Biochemical and Biophysical Research Communications* 2007; 359: 828-833.
- [56] Stolk J, Hiltermann T, Dijkman J, Verhoeven A. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. *American Journal of Respiratory Cell and Molecular Biology* 1994; 11: 95-102.

**Table 1.**  
Baseline fasting characteristics of study population.<sup>1</sup>

Characteristic	Value
Age (yrs)	26.6 ± 6.4
Height (m)	1.8 ± 0.1
Weight (kg)	76.6 ± 11.7
BMI (kg/m <sup>2</sup> )	24.2 ± 2.4
Waist circumference (cm)	81.9 ± 5.7
BP (mmHg)	
Systolic	121.2 ± 10.8
Diastolic	70.3 ± 8.0
Total cholesterol (mmol/l)	4.4 ± 0.8
Glucose (mmol/l)	5.3 ± 0.4
TAG (mmol/l)	0.8 ± 0.3
Brachial artery diameter (mm)	4.1 ± 0.5
FMD %	4.8 ± 1.6

<sup>1</sup> Values are means ± SD. (n=19).



**Table 2.**Compositional analysis of white, non-treated high fibre and enzyme-treated high fibre flatbreads.<sup>1</sup>

Compounds	Composition		
	White	Non-Treated High Fibre	Enzyme-treated High Fibre
White flour (%)	60.5	0.0	0
High Fibre flour (%)	0.0	60.5	60.5
Water (%)	34.8	34.8	34.8
Ultraflo L ® activated (%)	0.0	0.0	3.9
Ultraflo L ® de-activated (%)	3.9	3.9	0
Salt (%)	0.8	0.8	0.8
Energy (k joules) (kj/100g)	1169.0	1193.0	1247.0
Energy (k calories) (kcal/100g)	276.0	282.0	294.0
Protein (g/100g)	7.70	8.90	9.20
Total Carbohydrate (g/100g)	60.60	61.10	63.00
Total sugars (g/100g)	3.30	4.00	3.70
Fat (g/100g)	0.80	1.20	1.30
Saturates (g/100g)	0.14	0.24	0.26
Monounsaturates (g/100g)	1.23	0.24	0.18
Polyunsaturates (g/100g)	0.39	0.67	0.80
Trans fatty acids (g/100g)	<0.1	<0.1	<0.1
Total fibre (g/100g)	2.40	4.60	3.20
Sodium (mg/100g)	315.00	320.00	315.00
Moisture content (g/100g)	29.70	27.30	25.00
Ash content (g/100g)	1.18	1.48	1.54
Free FA (mg/100g)	0.53	2.60	15.80
Conjugated FA (mg/100g)	0.01	1.47	0.33
Bound FA (mg/100g)	1.00	16.90	9.43
Total FA (mg/100g)	1.54	20.97	25.56

364 <sup>1</sup> Values based on freeze dried flatbread.

365

**Table 3.** Acute effects of interventions on blood pressure, heart rate and DVP.<sup>1</sup>

	Baseline	2h	5h	7h
Systolic blood pressure				
(mm Hg)				
White	124 ± 2	121 ± 2	120 ± 3	121 ± 2
Non-Treated High Fibre	121 ± 2	120 ± 2	120 ± 2	121 ± 2
Enzyme-Treated High Fibre	121 ± 2	121 ± 2	120 ± 2	120 ± 2
Diastolic blood pressure				
(mm Hg)				
White	71 ± 1	68 ± 1	67 ± 1	72 ± 2
Non-Treated High Fibre	73 ± 2	68 ± 1	68 ± 2	71 ± 2
Enzyme-Treated High Fibre	71 ± 1	69 ± 1	67 ± 1	71 ± 1
Heart rate (beats/min)				
White	56 ± 2	58 ± 2	59 ± 2	57 ± 2
Non-Treated High Fibre	59 ± 2	60 ± 2	62 ± 2	59 ± 2
Enzyme-Treated High Fibre	59 ± 2	61 ± 2	60 ± 2	60 ± 2
DVP-SI (m/s)				
White	5.14 ± 0.8	5.3 ± 0.1	5.2 ± 0.1	5.6 ± 0.4
Non-Treated High Fibre	5.2 ± 0.3	5.5 ± 0.4	5.5 ± 0.4	5.4 ± 0.5
Enzyme-Treated High Fibre	5.5 ± 0.3	5.4 ± 0.4	5.5 ± 0.4	5.4 ± 0.4
DVP-RI (%)				
White	67 ± 12	66.6 ± 13	60.7 ± 13	62.1 ± 10
Non-Treated High Fibre	64.2 ± 15	63.9 ± 10	60.5 ± 11	60.5 ± 7
Enzyme-Treated High Fibre	66.2 ± 12	62.7 ± 14	62.1 ± 14	61 ± 12

<sup>1</sup> Values are means ± SEM. (n=19).

368 **Figure Legends.**

369 **Figure 1.** Consort Diagram. Flow diagram of the progress through the phases of the randomised  
370 clinical trial indicating participant numbers at enrolment, intervention allocation, follow-up, and  
371 data analysis.

372

373 **Figure 2.** Time dependent changes in FMD (n=19, mean  $\pm$  SD) following consumption of enzyme-  
374 treated high fibre ( $\blacktriangle$ ), non-treated high fibre ( $\blacksquare$ ) and white bread ( $\bullet$ ). Data were analyzed using 2-  
375 way ANOVA with post-hoc analysis conducted by using a Bonferroni multiple-comparisons test.  
376 Levels of significance between samples are indicated as follows: enzyme-treated high fibre  
377 flatbread versus white flatbread; 2 h (\*  $p < 0.05$ ), 5 h (\*\*  $p < 0.01$ ) and 7 h (\*  $p < 0.05$ ) and enzyme-  
378 treated high fibre flatbread vs non-treated high fibre flatbread 5 h (b:  $p < 0.01$ ).

379

380 **Figure 3.** Response of forearm skin erythrocyte flux following the iontophoresis of (A)  
381 acetylcholine chloride and (B) sodium nitroprusside (n=19) after consumption of white ( $\bullet$ ), non-  
382 treated high fibre ( $\blacksquare$ ) and enzyme-treated high fibre ( $\blacktriangle$ ) flatbread. Values are means  $\pm$  SEM.

383

384 **Figure 4.** (A). Total phenolic acids, in plasma at baseline, 2, 5 and 7 h following consumption of  
385 white ( $\bullet$ ), non-treated high fibre ( $\blacksquare$ ) and enzyme-treated high fibre ( $\blacktriangle$ ) flatbread (n=18; mean  $\pm$   
386 SEM). (B). Concentration of free FA in plasma at baseline, 2, 5 and 7 h following consumption of  
387 white ( $\bullet$ ), non-treated high fibre ( $\blacksquare$ ) and enzyme-treated high fibre ( $\blacktriangle$ ) flatbread (n=18; mean  $\pm$   
388 SEM). Data were measured using 2-factor repeated measures ANOVA with time and treatment as  
389 the 2 factors. Post hoc analysis was conducted using a Bonferroni multiple comparisons test. a:  
390 white vs enzyme-treated high fibre,  $p < 0.001$ ; b: white vs enzyme-treated high fibre,  $p < 0.01$ ; c: non-  
391 treated high fibre vs enzyme treated high fibre,  $p < 0.001$ ; d: non-treated high fibre vs enzyme-  
392 treated high fibre,  $p < 0.5$ .